Mechanism of Action of SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Primary Renal Mechanism
SGLT2 inhibitors block the sodium-glucose cotransporter 2 (SGLT2) protein located in the S1 and S2 segments of the proximal convoluted tubule in the kidneys, preventing reabsorption of filtered glucose and causing increased urinary glucose excretion (glucosuria). 1, 2
- Under normal physiology, SGLT2 is responsible for reabsorbing approximately 90% of filtered glucose from the tubular lumen back into the systemic circulation 3, 2, 4
- In healthy humans, the kidneys filter 160-180 grams of glucose daily (roughly 30% of daily caloric intake), which is normally completely reabsorbed 4
- In diabetes, hyperglycemia increases filtered and reabsorbed glucose by two- to three-fold 4
Glucose Threshold and Saturation Kinetics
- The renal glucose threshold is approximately 180 mg/dL; when plasma glucose exceeds this level, SGLT2 transporters become saturated and glucosuria begins to occur naturally 5, 3
- SGLT2 inhibitors lower this threshold pharmacologically, promoting glucosuria even at lower glucose levels 5, 2
- This mechanism results in excretion of approximately 70 grams of glucose daily in patients taking 5-10 mg doses 2
Insulin-Independent Action
- SGLT2 inhibitors work completely independently of insulin secretion or β-cell function, allowing their use across all stages of diabetes regardless of disease duration 5, 3, 6
- This insulin-independent mechanism confers a low intrinsic risk of hypoglycemia when used alone or with metformin 5, 3, 6
- By reducing glucotoxicity, SGLT2 inhibition gradually improves β-cell function and enhances peripheral insulin sensitivity over time 3, 7
Additional Renal Physiological Effects Beyond Glucose
- SGLT2 inhibitors reduce sodium reabsorption and increase sodium delivery to the distal tubule, triggering tubuloglomerular feedback 2
- This mechanism decreases intraglomerular pressure, which provides renal protective effects 2
- SGLT2 inhibition reduces oxygen consumption and ATP demand by proximal tubular cells, thereby alleviating renal cortical hypoxia that characteristically develops in diabetes 3, 8
Selectivity Profile Among SGLT2 Inhibitors
- Dapagliflozin, empagliflozin, and ertugliflozin are the most selective inhibitors for SGLT2 over SGLT1 1, 3
- Canagliflozin has greater SGLT1 inhibition, which affects intestinal glucose absorption and may elevate circulating GLP-1 levels 1, 9
- Sotagliflozin is classified as a dual SGLT1/SGLT2 inhibitor with the highest affinity for SGLT1 1
Cardiovascular and Hemodynamic Mechanisms
- SGLT2 inhibitors lower both preload and afterload of the heart through volume reduction and decreased sodium reabsorption 2
- They downregulate sympathetic nervous system activity 2
- These agents reduce systolic blood pressure by 3-5 mmHg through osmotic diuresis 5
Metabolic Effects
- SGLT2 inhibitors reduce HbA1c by 0.5-1.0% 5
- They promote weight loss of 1.5-3.5 kg through caloric loss via glucosuria 5
- The glucose-lowering efficacy depends on renal function (filtered glucose load = plasma glucose × GFR) and progressively declines as eGFR falls below 45 mL/min/1.73 m² 3, 2
Central Nervous System Expression
- SGLT2 is expressed at low levels in various brain regions including the cerebellum, hippocampus, and frontal cortex 1, 3
- This CNS expression may contribute to potential neuroprotective effects observed in preclinical studies, though clinical evidence remains limited 1
Pleiotropic Cardiorenal Benefits
- The cardiovascular and kidney benefits of SGLT2 inhibitors are out of proportion to their glucose-lowering effects and persist even when glycemic efficacy is lost at lower eGFR levels 3
- These benefits extend across all eGFR categories down to 20 mL/min/1.73 m² 3
- SGLT2 inhibitors significantly reduce mortality from major adverse cardiovascular events (MACE), hospitalizations for heart failure, and risk of end-stage renal disease 5, 3